Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

Inclusion Criteria: * Relapsed or refractory acute myelogenous or lymphoid leukemia * Chronic myelogenous leukemia in accelerated phase or blast-crisis * Chronic myelogenous leukemia in second or subsequent chronic phase * Recurrent or refractory malignant lymphoma or Hodgkin's disease * Multiple myeloma at high risk for disease recurrence * Chronic lymphocytic leukemia, relapsed or with poor prognostic features * Other Myeloproliferative disorder (polycythemia vera, essential thrombocythemia, myelofibrosis) with poor prognostic features * Myelodysplastic syndromes (including PNH) with \> 5% blasts * Zubroid performance status \< 2 (See Appendix B) * Life expectancy is not severely limited by concomitant illness * Adequate cardiac and pulmonary function. Patients with decreased LVEF or PFTS will be evaluated by cardiology or pulmonary prior to enrollment on this protocol * Calculated Creatinine Clearance \> 50 ml/min * Serum bilirubin 2.0 mg/dl, SGPT \< 3x upper limit of normal * No evidence of chronic active hepatitis or cirrhosis * HIV-negative * Patient is not pregnant * Patient or guardian able to sign informed consent Exclusion Criteria: * Clinical progression